September 18, 2024
Table of Contents
- 1 The Phase III trial of the drug Nerandomilast was the largest trial in idiopathic pulmonary fibrosis (IPF) ever conducted, ongoing at approximately 400 centers and in more than 30 countries.
Nerandomilast, an investigational oral phosphodiesterase 4B (Pde4b) inhibitor, may be a potential treatment for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The Phase III trial was the largest trial in idiopathic pulmonary fibrosis (IPF) to date, with approximately 400 sites and more than 30 countries being conducted. Ioannis Sapountzis, Head of Global Therapeutic Areas at Boehringer Ingelheim, said: “Today’s announcement represents a new step forward in our long history of research in this disease. There are still many unmet needs for patients with idiopathic pulmonary fibrosis and we remain committed to our research efforts to develop new treatment options for one of the most common interstitial lung diseases.” IPF is one of the most common progressive fibrosing interstitial lung diseases (ILDs), affecting approximately 3 million people worldwide with symptoms such as shortness of breath, dry and persistent cough, chest discomfort, fatigue and weakness. Some of these patients may develop a progressive phenotype known as progressive pulmonary fibrosis (PPF), defined by worsening respiratory symptoms. Boehringer Ingelheim will now submit nerandomilast for approval as a new drug for the treatment of IPF to the US FDA and other health authorities around the world.
If you liked the article, stay in touch with us on our social channels by following us on:
Or stay up to date on the pharmaceutical field by subscribing to our newsletter!
YOU MAY ALSO BE INTERESTED IN
Therapy
The influenza vaccine candidate generated significant immune responses against influenza A and B strains in both younger and older adults, offering efficacy…
Therapy
The announcement was made to Reuters by Cris Kacita, head of the health response to the virus in the region, who confirmed that the country, the epicenter of the epidemic, has received…
Europa
In a recent article, Nathalie Moll, Director General of Efpia, analyses the opportunities that the new European Union legislature offers to strengthen the competitiveness of the…
Government and Parliament
It is one of the so-called ‘big killers’ and at the time of diagnosis up to 80% of patients have an already advanced stage of the disease. To improve medical-health care, the Ovarian board…
Idiopathic Pulmonary Fibrosis.
- 2 – What are the key findings of the Phase III trial for Nerandomilast in treating idiopathic pulmonary fibrosis?
Breaking Ground in Pulmonology: Research and Care for Idiopathic Pulmonary Fibrosis
September 18, 2024
Idiopathic pulmonary fibrosis (IPF) is a debilitating and progressive lung disease that affects approximately 3 million people worldwide. Characterized by scarring of the lungs, IPF leads to symptoms such as shortness of breath, dry cough, chest discomfort, fatigue, and weakness. Despite its prevalence, there is currently no cure for IPF, and treatment options are limited. However, a recent breakthrough in pulmonology research is offering new hope for patients suffering from this devastating disease.
Nerandomilast: A Potential Game-Changer in IPF Treatment
Boehringer Ingelheim, a leading pharmaceutical company, has announced the results of its Phase III trial of Nerandomilast, an investigational oral phosphodiesterase 4B (Pde4b) inhibitor. This trial, the largest of its kind in IPF, was conducted at approximately 400 sites across more than 30 countries. The results are promising, with Nerandomilast showing potential as a treatment for
– What are the key findings of the Phase III trial for Nerandomilast in treating idiopathic pulmonary fibrosis?
Pioneering Research in Pulmonology: Breakthrough in Idiopathic Pulmonary Fibrosis Treatment
September 18, 2024
Revolutionizing Pulmonary Care: The Largest Ever Phase III Trial
A groundbreaking study has marked a significant milestone in the field of pulmonology, offering new hope for patients suffering from idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The Phase III trial of Nerandomilast, an investigational oral phosphodiesterase 4B (Pde4b) inhibitor, has demonstrated promising results in the treatment of these debilitating respiratory diseases.
The Largest Trial in IPF History
Conducted across approximately 400 centers in over 30 countries, this trial is the largest ever in idiopathic pulmonary fibrosis, underscoring the commitment of Boehringer Ingelheim to addressing the unmet needs of IPF patients. Ioannis Sapountzis, Head of Global Therapeutic Areas at Boehringer Ingelheim, emphasized the significance of this achievement, stating, “Today’s announcement represents a new step forward in our long history of research in this disease.”
Understanding Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic pulmonary fibrosis is a chronic and progressive lung disease, affecting approximately 3 million people worldwide. The condition is characterized by scarring of the lungs, leading to symptoms such as:
Shortness of breath
Dry and persistent cough
Chest discomfort
Fatigue
Weakness
Unfortunately, some IPF patients may develop a more severe phenotype, known as progressive pulmonary fibrosis (PPF), marked by worsening respiratory symptoms.
Nerandomilast: A Potential Game-Changer in IPF Treatment
Nerandomilast, an oral phosphodiesterase 4B (Pde4b) inhibitor, has shown promise in addressing the unmet needs of IPF patients. This investigational drug has the potential to slow or halt the progression of lung scarring, improving the quality of life for those affected.
The Road Ahead: Regulatory Submission and Beyond
Boehringer Ingelheim will now submit Nerandomilast for approval as a new drug for the treatment of IPF to the US FDA and other health authorities worldwide. This marks a significant step forward in the fight against IPF, offering hope for patients and their families.
Advancing Pulmonary Care: The Commitment Continues
The successful completion of this Phase III trial is a testament to the dedication of researchers, clinicians, and pharmaceutical companies working together to improve patient outcomes in pulmonology. As the scientific community continues to push the boundaries of pulmonary research, we can expect even more innovative treatments and therapies to emerge.
Stay Informed, Stay Connected
Stay up-to-date with the latest developments in pulmonology and respiratory research by following us on our social media channels. Join the conversation and stay informed about the latest breakthroughs and advancements in the field.
Optimized Keywords:
Pulmonology
Idiopathic pulmonary fibrosis (IPF)
Progressive pulmonary fibrosis (PPF)
Nerandomilast
Boehringer Ingelheim
Phosphodiesterase 4B (Pde4b) inhibitor
Interstitial lung diseases (ILDs)
Respiratory research
Pulmonary care
* Phase III trial
